Quick Answer
Entrada Therapeutics, Inc. reported Earnings Per Share Diluted of $3.47 (loss) per share for the year ending 2025.
- Entrada Therapeutics, Inc. showed a decrease of -306.5% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Entrada Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $6.13 (loss) per share | Q1 2021: $6.67 (loss) per share | Q2 2021: $7.56 (loss) per share | Q3 2021: $9.78 (loss) per share | Q1 2022: $0.69 (loss) per share | Q2 2022: $0.74 (loss) per share | Q3 2022: $0.80 (loss) per share | Q1 2023: $0.21 (loss) per share | Q2 2023: $0.78 (loss) per share | Q3 2023: $1.02 per share | Q1 2024: $0.68 per share | Q2 2024: $1.55 per share | Q3 2024: $0.35 (loss) per share | Q1 2025: $0.42 (loss) per share | Q2 2025: $1.04 (loss) per share | Q3 2025: $1.06 (loss) per share.
- Over the full 6 years of available data (2020 to 2025), Entrada Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 85.5%.
- Historical annual values: Fiscal year 2025: $3.47 (loss) per share | Fiscal year 2024: $1.68 per share | Fiscal year 2023: $0.20 (loss) per share | Fiscal year 2022: $3.02 (loss) per share | Fiscal year 2021: $8.16 (loss) per share | Fiscal year 2020: $24.00 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: